Recently, the Sichuan Provincial Health Commission, the Provincial Department of Finance, and the Provincial Drug Administration jointly issued the “Sichuan Provincial Special Financial Assistance Implementation Plan for Class 1 Innovative Drug Clinical Trials”, which clearly grants special financial subsidies to units carrying out clinical trials of Class 1 innovative drugs in Sichuan, with a cumulative annual subsidy of up to 50 million yuan; a one-time subsidy of up to 2 million yuan for projects terminated in Phase III R&D under compliance conditions, releasing a clear signal of “encouraging innovation and tolerating failure”, stimulating the collaborative innovation vitality of medical institutions and pharmaceutical companies across the province.

Zhitongcaijing · 2d ago
Recently, the Sichuan Provincial Health Commission, the Provincial Department of Finance, and the Provincial Drug Administration jointly issued the “Sichuan Provincial Special Financial Assistance Implementation Plan for Class 1 Innovative Drug Clinical Trials”, which clearly grants special financial subsidies to units carrying out clinical trials of Class 1 innovative drugs in Sichuan, with a cumulative annual subsidy of up to 50 million yuan; a one-time subsidy of up to 2 million yuan for projects terminated in Phase III R&D under compliance conditions, releasing a clear signal of “encouraging innovation and tolerating failure”, stimulating the collaborative innovation vitality of medical institutions and pharmaceutical companies across the province.